Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Small entity compliance guides

This article was originally published in The Tan Sheet

Executive Summary

FDA proposes small entity compliance guides for separate final rules concerning ephedra and nutrition claims in order to help small businesses understand the regulations. In a July 17 Federal Register notice, FDA solicits comments on a 1guide for a 2004 final rule declaring dietary supplements containing ephedrine alkaloids adulterated for presenting an unreasonable risk of illness or injury under conditions of use recommended in labeling (2"The Tan Sheet" Feb. 16, 2004, p. 10). A July 18 notice says FDA is accepting comments on an 3SECG on a 1997 final rule amending regulations defining the terms "high potency" and "antioxidant" for use in supplement nutrient content claims (4"The Tan Sheet" Sept. 29, 1997, p. 1)...
Advertisement
Advertisement

Related Content

Topics

Advertisement
UsernamePublicRestriction

Register

PS101902

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel